Free Trial

Envista (NVST) Competitors

Envista logo
$18.02 +0.45 (+2.58%)
Closing price 03/27/2025 03:59 PM Eastern
Extended Trading
$18.04 +0.01 (+0.06%)
As of 03/27/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NVST vs. PEN, STVN, GKOS, BLCO, INSP, NARI, IRTC, PRCT, TMDX, and SLNO

Should you be buying Envista stock or one of its competitors? The main competitors of Envista include Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), PROCEPT BioRobotics (PRCT), TransMedics Group (TMDX), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry.

Envista vs.

Envista (NYSE:NVST) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.

In the previous week, Penumbra had 9 more articles in the media than Envista. MarketBeat recorded 12 mentions for Penumbra and 3 mentions for Envista. Envista's average media sentiment score of 1.20 beat Penumbra's score of 0.97 indicating that Envista is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Envista
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Penumbra
7 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

88.9% of Penumbra shares are owned by institutional investors. 1.3% of Envista shares are owned by insiders. Comparatively, 5.0% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Penumbra has a net margin of 1.17% compared to Envista's net margin of -44.56%. Penumbra's return on equity of 9.74% beat Envista's return on equity.

Company Net Margins Return on Equity Return on Assets
Envista-44.56% 3.86% 2.21%
Penumbra 1.17%9.74%7.35%

Penumbra received 796 more outperform votes than Envista when rated by MarketBeat users. Likewise, 80.27% of users gave Penumbra an outperform vote while only 33.33% of users gave Envista an outperform vote.

CompanyUnderperformOutperform
EnvistaOutperform Votes
34
33.33%
Underperform Votes
68
66.67%
PenumbraOutperform Votes
830
80.27%
Underperform Votes
204
19.73%

Penumbra has lower revenue, but higher earnings than Envista. Envista is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Envista$2.51B1.24-$1.12B-$6.49-2.78
Penumbra$1.19B8.67$90.95M$0.34790.84

Envista presently has a consensus price target of $20.18, indicating a potential upside of 11.95%. Penumbra has a consensus price target of $294.47, indicating a potential upside of 9.51%. Given Envista's higher probable upside, analysts clearly believe Envista is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Envista
2 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.07
Penumbra
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

Envista has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Penumbra beats Envista on 15 of the 19 factors compared between the two stocks.

Remove Ads
Get Envista News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVST and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVST vs. The Competition

MetricEnvistaDental equipment & supplies IndustryMedical SectorNYSE Exchange
Market Cap$3.10B$3.64B$5.64B$19.62B
Dividend YieldN/A2.17%4.57%3.75%
P/E Ratio-2.7836.2123.1433.60
Price / Sales1.241.39384.1127.47
Price / Cash12.916.5738.1617.54
Price / Book1.060.716.954.60
Net Income-$1.12B-$146.24M$3.20B$1.02B
7 Day Performance8.42%0.85%-2.28%0.37%
1 Month Performance-9.54%-8.15%2.88%-2.45%
1 Year Performance-15.74%224.50%10.87%5.03%

Envista Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVST
Envista
4.1731 of 5 stars
$18.02
+2.6%
$20.18
+12.0%
-16.3%$3.10B$2.51B-2.7812,700
PEN
Penumbra
4.4304 of 5 stars
$276.24
+1.3%
$294.47
+6.6%
+18.9%$10.64B$1.19B812.464,200Insider Trade
STVN
Stevanato Group
1.7052 of 5 stars
€20.71
+3.4%
N/A-36.4%$6.27B$1.10B44.065,635Positive News
GKOS
Glaukos
4.4276 of 5 stars
$103.12
+0.9%
$163.25
+58.3%
+11.8%$5.83B$383.48M-35.93780Insider Trade
Positive News
BLCO
Bausch + Lomb
3.9743 of 5 stars
$15.39
+0.3%
$20.00
+29.9%
-12.9%$5.43B$4.79B-16.9212,500News Coverage
Gap Down
INSP
Inspire Medical Systems
4.8898 of 5 stars
$166.59
+2.7%
$228.82
+37.4%
-24.6%$4.94B$802.80M96.291,246Positive News
NARI
Inari Medical
1.0521 of 5 stars
$79.97
flat
$68.00
-15.0%
N/A$4.68B$493.63M-59.24800
IRTC
iRhythm Technologies
2.0958 of 5 stars
$103.70
+3.0%
$119.73
+15.5%
-8.3%$3.26B$591.84M-28.491,790News Coverage
Positive News
PRCT
PROCEPT BioRobotics
2.7097 of 5 stars
$59.03
+2.4%
$94.29
+59.7%
+26.5%$3.24B$224.50M-30.27430Positive News
TMDX
TransMedics Group
2.6238 of 5 stars
$67.69
-1.2%
$122.70
+81.3%
-5.0%$2.28B$441.54M72.01210Analyst Forecast
SLNO
Soleno Therapeutics
4.6682 of 5 stars
$49.63
+0.6%
$71.20
+43.5%
+57.3%$2.28BN/A-14.9530Analyst Forecast
News Coverage
Gap Up
Remove Ads

Related Companies and Tools


This page (NYSE:NVST) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners